Bristol John W & Co. Inc. NY Sells 15,461 Shares of Johnson & Johnson (NYSE:JNJ)

Bristol John W & Co. Inc. NY trimmed its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 507,007 shares of the company's stock after selling 15,461 shares during the period. Bristol John W & Co. Inc. NY's holdings in Johnson & Johnson were worth $73,323,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Yoffe Investment Management LLC bought a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $542,000. LifeWealth Investments LLC bought a new position in Johnson & Johnson during the 4th quarter valued at approximately $226,000. Capital A Wealth Management LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at $50,000. LM Advisors LLC boosted its holdings in Johnson & Johnson by 54.3% in the fourth quarter. LM Advisors LLC now owns 12,245 shares of the company's stock worth $1,771,000 after acquiring an additional 4,311 shares in the last quarter. Finally, Lakeshore Capital Group Inc. purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth $999,000. Institutional investors own 69.55% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on JNJ shares. Royal Bank of Canada reiterated an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their target price for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Wall Street Zen cut Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. Eleven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded up $0.53 during midday trading on Thursday, hitting $152.96. The company had a trading volume of 2,353,932 shares, compared to its average volume of 7,931,169. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The company has a fifty day moving average of $154.63 and a two-hundred day moving average of $153.64. The company has a market cap of $368.04 billion, a price-to-earnings ratio of 23.00, a PEG ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. On average, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.40%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.